治疗糖尿病相关并发症的治疗干预措施
Dharmendra Pradhan1, Prafulla Kumar Sahu1, Sukumar Purohit1
1School of Pharmacy, Centurion University of Technology and Management, Odisha, India.
Current diabetes reviews
|May 6, 2024
概括
本综述总结了全球健康危机糖尿病 (DM) 的理解和治疗方面的进展. 它涵盖并发症,天然产品疗法和新的治疗方法,如干细胞疗法,以改善患者的治疗结果.
科学领域:
- 内分泌学和新陈代谢学
- 药理学和治疗学 药理学和治疗学
背景情况:
- 糖尿病 (DM) 影响全球超过5.37亿人,造成严重的发病率和死亡率风险.
- 了解DM复杂的病理生理学和进展对于有效的管理至关重要.
研究的目的:
- 审查高血糖症及其并发症的发病性.
- 巩固目前和新兴的DM最佳治疗策略.
主要方法:
- 过去二十年的传统文学综述.
- 在著名的数据库 (PubMed,Scopus,Google Scholar,Web of Science,ClinicalTrials.gov) 搜索了"糖尿病"",并发症"和"新疗法"等关键词.
主要成果:
- 讨论了宏血管 (动脉样硬化,心血管疾病,PAD,中风) 和微血管 (脏病,视网膜病,神经病) 的并发症.
- 突出药理学,非药理学和天然产品干预措施,针对代谢途径和氧化应激.
- 探索了包括遗传,干细胞和免疫调节方法在内的新疗法,以及精准医学.
结论:
- 对于临床医生来说,对DM进步的更好理解至关重要.
- 这些知识有助于确定对患者最有效的治疗干预措施.
相关概念视频
Diabetes: Management and Pharmacotherapy
266
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
266
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Diabetes: Symptoms, Diagnosis, and Complications
526
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
526
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Insulin: Dosing Regimen and Adverse Effects
167
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
167


